Eupraxia Pharmaceuticals, Inc. EPRX 深 滬
交易中 05-18 10:15:22 美东时间
6.97
+0.050
+0.72%
華盛通- 最 高7.7331
- 今 開6.97
- 成交量 5792股
- 最 低 6.97
- 昨 收 6.92
- 總市值 42.87万
- 52周最高 9.32
- 市盈率 靜 --
- 換手率 0.01%
- 52周最低 3.8173
- 委 比 20.00%
- 總股本 6.15万
- 歷史最高 9.32
- 量 比 0.66
- 振 幅 11.03%
- 歷史最低 2.20
- 每 手 1
- 風險率 1.37%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Eupraxia Pharmaceuticals Q1 EPS $(0.23) Misses $(0.22) Estimate
Eupraxia Pharmaceuticals (NASDAQ:EPRX) reported quarterly losses of $(0.23) per share which missed the analyst consensus estimate of $(0.22) by 4.55 percent. This is a 9.52 percent decrease over losses of $(0.21) per
05-13 05:08
Eupraxia Pharmaceuticals Reports First Quarter 2026 Financial Results
Eupraxia Pharmaceuticals Inc. reported positive clinical data and financial results for Q1 2026, highlighting significant progress in its EP-104GI treatment for Eosinophilic Esophagitis (EoE). The company completed a $63.2 million public offering to advance clinical trials and has sufficient cash reserves to fund operations into H2 2028. Recent highlights include near-complete tissue improvement in biopsy results and symptom data from the highest...
05-12 21:00
Eupraxia Reports Early Trial Results For EoE Drug, Doses Show Response In Mid-Stage Study
Eupraxia Pharmaceuticals Inc. ("Eupraxia" or the "Company") (NASDAQ:EPRX) (TSX:EPRX), a clinical-stage biotechnology company leveraging its proprietary Diffusphere™ technology designed to optimize local,
05-05 19:15
美股大行评级 | 巴克莱大幅上调希捷科技、西部数据目标价！联合健康、霍顿房屋、盈透证券、奎斯特诊疗等获多家机构上调目标价
今日重点评级关注：Piper Sandler：维持MeiraGTx Holdings"超配"评级，目标价从26美元升至30美元；康托·菲茨杰拉德：维持MKS Inc."超配"评级，目标价从300美元升至400美元
04-23 12:35
Eupraxia Pharma Announces 36-Week Tissue Health And Symptom Data From Patients In Highest Dose Cohort From Ongoing Phase 1b/2a Part Of RESOLVE Trial Evaluating EP-104GI For Treatment Of EoE
This is the first release of 36-week symptom response & tissue health data for the highest dose (Cohort 9) from the dose escalation portion of Eupraxia's RESOLVE trial. At 36 weeks, patients in Cohort 9
04-21 19:08
Eupraxia Pharmaceuticals to Present at Upcoming Investor Conferences
Eupraxia Pharmaceuticals Inc. announced that its management team will participate in upcoming investor conferences: the Raymond James Biotech Innovation Symposium on April 14, 2026, in New York, and the 2026 Bloom Burton & Co. Healthcare Investor Conference on April 21-22, 2026, in Toronto. The company, leveraging its proprietary Diffusphere™ technology for targeted drug delivery, is developing treatments for unmet medical needs, including EoE an...
04-13 12:00
Eupraxia Pharmaceuticals Boasts $900 Million Peak Sales Potential: Analyst
William Blair starts Eupraxia at Outperform as the analyst flags unmet need and sizable market potential.
03-24 01:59
美股大行评级 | 摩根大通上调哔哩哔哩至"超配"，目标价从27美元升至35美元；Rhythm遭花旗、大摩等多家机构下调目标价
今日重点评级关注：韦德布什：维持Black Diamond Therapeutic"跑赢大市"评级，目标价从13美元升至14美元；花旗：维持Olema Pharmaceuticals"买入"评级，目标价从60美元升至62美元
03-18 10:48
Semtech To Rally Around 18%? Here Are 10 Top Analyst Forecasts For Tuesday
Wall Street analysts changed outlook on top names: Morgan Stanley raised Lemonade's PT to $85, Mizuho cut Canadian Solar's PT to $19, Piper Sandler raised Tandem Diabetes' PT to $33, Stifel increased Ichor's PT to $55, Needham raised Semtech's PT to $105, HC Wainwright cut Eupraxia Pharma's PT to $11, Evercore ISI Group raised National Storage Affiliates Trust's PT to $41.
03-17 19:49
